Literature DB >> 21307846

Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.

Mateus M Bergamaschi1, Regina Helena Costa Queiroz, Marcos Hortes Nisihara Chagas, Danielle Chaves Gomes de Oliveira, Bruno Spinosa De Martinis, Flávio Kapczinski, João Quevedo, Rafael Roesler, Nadja Schröder, Antonio E Nardi, Rocio Martín-Santos, Jaime Eduardo Cecílio Hallak, Antonio Waldo Zuardi, José Alexandre S Crippa.   

Abstract

Generalized Social Anxiety Disorder (SAD) is one of the most common anxiety conditions with impairment in social life. Cannabidiol (CBD), one major non-psychotomimetic compound of the cannabis sativa plant, has shown anxiolytic effects both in humans and in animals. This preliminary study aimed to compare the effects of a simulation public speaking test (SPST) on healthy control (HC) patients and treatment-naïve SAD patients who received a single dose of CBD or placebo. A total of 24 never-treated patients with SAD were allocated to receive either CBD (600 mg; n=12) or placebo (placebo; n=12) in a double-blind randomized design 1 h and a half before the test. The same number of HC (n=12) performed the SPST without receiving any medication. Each volunteer participated in only one experimental session in a double-blind procedure. Subjective ratings on the Visual Analogue Mood Scale (VAMS) and Negative Self-Statement scale (SSPS-N) and physiological measures (blood pressure, heart rate, and skin conductance) were measured at six different time points during the SPST. The results were submitted to a repeated-measures analysis of variance. Pretreatment with CBD significantly reduced anxiety, cognitive impairment and discomfort in their speech performance, and significantly decreased alert in their anticipatory speech. The placebo group presented higher anxiety, cognitive impairment, discomfort, and alert levels when compared with the control group as assessed with the VAMS. The SSPS-N scores evidenced significant increases during the testing of placebo group that was almost abolished in the CBD group. No significant differences were observed between CBD and HC in SSPS-N scores or in the cognitive impairment, discomfort, and alert factors of VAMS. The increase in anxiety induced by the SPST on subjects with SAD was reduced with the use of CBD, resulting in a similar response as the HC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21307846      PMCID: PMC3079847          DOI: 10.1038/npp.2011.6

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  40 in total

1.  Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors.

Authors:  Vanessa de Paula Soares; Alline Cristina Campos; Valquíria Camin de Bortoli; Hélio Zangrossi; Francisco Silveira Guimarães; Antonio Waldo Zuardi
Journal:  Behav Brain Res       Date:  2010-05-08       Impact factor: 3.332

2.  National Science and Technology Institute for Translational Medicine (INCT-TM): advancing the field of translational medicine and mental health.

Authors:  Jaime E C Hallak; José Alexandre S Crippa; João Quevedo; Rafael Roesler; Nadja Schröder; Antonio Egidio Nardi; Flávio Kapczinski
Journal:  Braz J Psychiatry       Date:  2010-03       Impact factor: 2.697

Review 3.  Clinical practice guidelines. Management of anxiety disorders.

Authors: 
Journal:  Can J Psychiatry       Date:  2006-07       Impact factor: 4.356

4.  Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale.

Authors:  K M Connor; J R Davidson; L E Churchill; A Sherwood; E Foa; R H Weisler
Journal:  Br J Psychiatry       Date:  2000-04       Impact factor: 9.319

5.  Simulated public speaking as a model of clinical anxiety.

Authors:  D M McNair; L M Frankenthaler; T Czerlinsky; T W White; S Sasson; S Fisher
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

6.  Further study of the psychometric qualities of a brief screening tool for social phobia (MINI-SPIN) applied to clinical and nonclinical samples.

Authors:  Flávia de Lima Osório; José Alexandre S Crippa; Sonia Regina Loureiro
Journal:  Perspect Psychiatr Care       Date:  2010-10       Impact factor: 2.186

7.  Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence.

Authors:  Julia D Buckner; Norman B Schmidt; Alan R Lang; Jason W Small; Robert C Schlauch; Peter M Lewinsohn
Journal:  J Psychiatr Res       Date:  2007-02-23       Impact factor: 4.791

Review 8.  Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment.

Authors:  N Brunello; J A den Boer; L L Judd; S Kasper; J E Kelsey; M Lader; Y Lecrubier; J P Lepine; R B Lydiard; J Mendlewicz; S A Montgomery; G Racagni; M B Stein; H U Wittchen
Journal:  J Affect Disord       Date:  2000-10       Impact factor: 4.839

9.  Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol.

Authors:  Paolo Fusar-Poli; Paul Allen; Sagnik Bhattacharyya; José A Crippa; Andrea Mechelli; Stefan Borgwardt; Rocio Martin-Santos; Marc L Seal; Colin O'Carrol; Zerrin Atakan; Antonio W Zuardi; Philip McGuire
Journal:  Int J Neuropsychopharmacol       Date:  2009-09-24       Impact factor: 5.176

10.  Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.

Authors:  Paolo Fusar-Poli; José A Crippa; Sagnik Bhattacharyya; Stefan J Borgwardt; Paul Allen; Rocio Martin-Santos; Marc Seal; Simon A Surguladze; Colin O'Carrol; Zerrin Atakan; Antonio W Zuardi; Philip K McGuire
Journal:  Arch Gen Psychiatry       Date:  2009-01
View more
  183 in total

Review 1.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors:  Javier Fernández-Ruiz; Onintza Sagredo; M Ruth Pazos; Concepción García; Roger Pertwee; Raphael Mechoulam; José Martínez-Orgado
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

2.  Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers.

Authors:  Shanna Babalonis; Margaret Haney; Robert J Malcolm; Michelle R Lofwall; Victoria R Votaw; Steven Sparenborg; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2016-12-14       Impact factor: 4.492

3.  HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid.

Authors:  Christeene G Haj; Percy F Sumariwalla; Lumír Hanuš; Natalya M Kogan; Zhana Yektin; Raphael Mechoulam; Mark Feldmann; Ruth Gallily
Journal:  J Pharmacol Exp Ther       Date:  2015-08-13       Impact factor: 4.030

Review 4.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

5.  Do psychoactive drugs have a therapeutic role in compulsivity? Studies on schedule-induced polydipsia.

Authors:  Elena Martín-González; Ángeles Prados-Pardo; Santiago Mora; Pilar Flores; Margarita Moreno
Journal:  Psychopharmacology (Berl)       Date:  2018-01-08       Impact factor: 4.530

Review 6.  The Use of Cannabinoids in Treating Dementia.

Authors:  Megan Weier; Wayne Hall
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08       Impact factor: 5.081

Review 7.  Cannabinoids in experimental stroke: a systematic review and meta-analysis.

Authors:  Timothy J England; William H Hind; Nadiah A Rasid; Saoirse E O'Sullivan
Journal:  J Cereb Blood Flow Metab       Date:  2014-12-10       Impact factor: 6.200

Review 8.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

9.  Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine.

Authors:  Mateus M Bergamaschi; Allan Barnes; Regina H C Queiroz; Yasmin L Hurd; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-03-15       Impact factor: 4.142

Review 10.  Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Authors:  José Alexandre S Crippa; Jaime E C Hallak; Antônio W Zuardi; Francisco S Guimarães; Vitor Tumas; Rafael G Dos Santos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-31       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.